The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Jul. 23, 8:16 PM

Slide #2. La Jolla Pharmaceutical Company Secondary Offering

Company: La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Date announced: 7/22/2014
Shares Offered: 4,800,000
Date of Pricing: 7/23/2014
Price Per Share: $10.50
Secondary Offering Details: La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by La Jolla. updated 7/23 - La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about July 28, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.

La Jolla Pharmaceutical is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutics for chronic organ failure and cancer. Co.'s two product candidates are: GCS-100, which is targeting the galectin-3 protein and is in clinical trial for the treatment of chronic kidney disease; and LJPC-501, a peptide agonist of the renin-angiotensin system designed to restore kidney function in patients with hepatorenal syndrome. Co. has several product candidates in the early development stage, including LJPC-101, a subcutaneous formulation of GCS-100, LJPC-201, an oral galectin-3 inhibitor and LJPC-301, a monoclonal antibody designed to neutralize galectin-3.
Open the LJPC Page at The Online Investor »

Company Name:  La Jolla Pharmaceutical Co.
Sector:  Biotechnology

Open the LJPC Page at The Online Investor (in a new window) »

July 23, 2014    8:16 PM Eastern
Quotes delayed 20 minutes

Secondary Stock Offerings | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.